

**Higher activity than in the 1<sup>st</sup> quarter of 2008: + 1.8 %**

M€	2009	2008	Variation
<b>Turnover 1<sup>st</sup> quarter 2009</b>	18.19	17.88	+ 1.8 %

After a drop of – 2.6 % in the 4<sup>th</sup> quarter of 2008, Pharmagest Inter@ctive registered a slight progression in its turnover on 31st March 2009 of 1.8 % to 18.19 M€, versus 17.88 M€ in 31 March 2008.

**Activity in focus:**

- Turnover for sales configuration remains, continuing on from the 4<sup>th</sup> quarter of 2008, in slight decline (- 2.7 %) in relation to the 1<sup>st</sup> quarter of 2008. However, and after an especially difficult January, in the context of the economic crisis, Pharmagest Inter@ctive noted a slight improvement in its order books at the end of the quarter.
- The sale of licences, up 5.8 % in relation to the 1<sup>st</sup> quarter of 2008, benefiting from the effects of the offer from the Welcoop Group, systematically offering the «flagship» software from Pharmagest Inter@ctive, LGPI, to French pharmacies. Moreover, the cap of the 5000 Management Software with Integrated Portal (LGPI) installed has just been passed, that's to say, more than 50 % of the total number of clients are in France.
- High margin products and services (maintenance, Offimedia, Offisecurebox with telephony, etc.) are progressing significantly (turnover up by 23 % compared to the 1<sup>st</sup> quarter 2008) and represent an increase in the global turnover.
- «Laboratory» activity is still buoyant thanks to the direct command module integrated in IT solutions developed by Pharmagest. E-communication services and «online surveys» systems are also expanding.

**Outlook for 2009**

For the 2009 fiscal year, Pharmagest Inter@ctive will be concentrating on:

- good management of its operations;
- developing customer loyalty thanks to enhanced training and auxiliary efforts;
- promoting its different offers which have high added value, such as Offimedia, which permits its pharmacist clients to benefit from a real competitive lead, indispensable in the current economic context. It is to be noted moreover that Pharmagest Inter@ctive has acquired intangible assets of its main competitor: the Bordeaux company NOVAX. The Group thus strengthens its position in a significant manner in the point-of-sale advertising sector;

- strengthening area of activity in laboratories and advertising sales division offer. Pharmagest Inter@ctive intends to noticeably enhance the number of agreements made with laboratories, thus enabling pharmacists to benefit from a comprehensive catalogue to carry out their direct orders;
- consolidating its positions in Belgium;
- displaying and enhancing the status of its new expertise in IT solutions for EHPAD (care centres for elderly people);
- studying growth externally, in Europe.

#### **Financial calendar:**

- Company Annual General Meeting, 19 June 2009 in Paris – Pharmagest Inter@ctive S.A. reiterates that at the customary AGM, on 19 June 2009, it is to propose the payment of a dividend of 1.35 € tp to shareholders for the 2008 fiscal year, up 3.8 % compared with the previous fiscal year.
- publication of the CA T2; 6 August, 2009
- publication of quarterly results; 29 August, 2009

#### **The Pharmagest Inter@ctive Group:**

The Pharmagest Inter@ctive Group – CIP SA is the leader in medical IT systems in France, with 43 % market shares, 9800 clients and 600 contributors. Since September 2007, the Group has also been present in Northern Europe, having 12.7 % market shares in Belgium and in Luxembourg.

Having a special partnership with pharmacists for more than 20 years, Pharmagest Inter@ctive devises innovative IT solutions for pharmacies, and develops E-Business E-Media activity which has great potential for laboratories.

The Group also develops original software solutions for EHPAD centres, and reception centres for older people.

The first Management Software with Integrated Portal (Logiciel de Gestion à Portail Intégré - LGPI®), creating value for the patient, the pharmacist and the laboratory, stimulates sales, optimises purchases and enriches advice to the patient. It is also the first permanent impact media in pharmacies, ensuring laboratories have direct communication with the pharmacist and patients.

Listed on NYSE Euronext Paris™ - Compartiment C  
Under the CAC SMALL90 index and SBF 250 by inclusion

ISIN: FR 0000077687 – Reuters: PHA.PA – Bloomberg: - PMGI FP

*Find out the latest news from the group at [www.pharmagest.com](http://www.pharmagest.com)*



**Chairman of the Board of Directors:**  
Michel MATHIE U

**Managing Director:**  
Thierry CHAPUSOT  
Tel. 03 83 15 90 67 - [thierry.chapusot@pharmagest.com](mailto:thierry.chapusot@pharmagest.com)

**Investor Relations Analysts:**  
Group Financial and Administrative Director: Anne LHOTE  
Tel. 03 83 15 90 67 – [anne.lhote@welcoop.com](mailto:anne.lhote@welcoop.com)

**Media Relations:**

FIN'EXTENSO – Isabelle APRILE

Tel. 01 39 97 61 22 - [i.aprile@finextenso.fr](mailto:i.aprile@finextenso.fr)